NASDAQ$TNXP
Tonix Pharmaceuticals Holding Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Tonix reported financial results for the third quarter ended September 30, 2022 and provided an overview of recent operational highlights.
Tonix Pharmaceuticals reported a net loss of $29.0 million, or $0.69 per share, for the third quarter ended September 30, 2022. The company's cash and cash equivalents totaled approximately $140 million as of September 30, 2022. Tonix is advancing multiple programs within its pipeline, with several Phase 2 or 3 studies expected to be in the clinic by the first quarter of 2023.
- Cash and cash equivalents totaled approximately $140 million at September 30, 2022.
- A confirmatory Phase 3 study for fibromyalgia and a potentially pivotal Phase 2 study for Long COVID have commenced.
- Interim data from TNX-102 SL studies in Fibromyalgia and Long COVID are expected in the second quarter of 2023.
- Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. are operational.
Headline financials
Revenue & EPS history
Tonix · Revenue · Quarterly
$6.88M
Forward guidance
Tonix expects R&D expenses to increase throughout the remainder of 2022 as it moves its clinical development programs forward and invests in its development pipeline.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-1.2%
Avg return
Earnings day
+0.5%
Avg return
5 days after
-12.7%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+12.9%
Q1 2016
Best reaction
-31.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | +11.7% | — | |
| Q4 2025 | +0.0% | +19.1% | -2.0% | |
| Q3 2025 | -0.9% | -6.5% | +16.2% | |
| Q1 2025 | +5.2% | +45.9% | +80.0% | |
| Q4 2024 | -2.4% | +48.6% | -23.5% | |
| Q3 2024 | +0.6% | -7.1% | +64.3% | |
| Q2 2024 | -2.6% | -21.7% | -65.2% | |
| Q1 2024 | +4.8% | +17.6% | -79.6% | |
| Q4 2023 | +2.5% | -10.5% | -5.3% | |
| Q3 2023 | -4.3% | -6.1% | -18.4% | |
| Q2 2023 | +1.8% | +1.1% | -4.2% | |
| Q1 2023 | -31.7% | -40.6% | -41.2% | |
| Q4 2022 | +8.7% | -3.2% | -9.7% | |
| Q3 2022 | +1.5% | +4.4% | -17.8% | |
| Q2 2022 | -11.4% | -11.4% | -42.4% | |
| Q1 2022 | -5.4% | -7.1% | -49.3% | |
| Q4 2021 | -4.7% | +9.1% | -13.6% | |
| Q3 2021 | +7.4% | -1.8% | -18.2% | |
| Q2 2021 | +12.5% | -1.4% | -2.9% | |
| Q1 2021 | -2.8% | +0.0% | +22.6% | |
| Q4 2020 | +0.0% | +14.2% | -14.2% | |
| Q3 2020 | -1.8% | +10.7% | +16.1% | |
| Q2 2020 | -12.1% | -12.1% | -30.2% | |
| Q1 2020 | -3.3% | -2.8% | -4.2% | |
| Q4 2019 | -13.2% | -14.1% | -20.0% | |
| Q3 2019 | -3.1% | +0.8% | -59.5% | |
| Q2 2019 | +0.5% | +0.0% | +4.3% | |
| Q1 2019 | -9.5% | -18.0% | -21.0% | |
| Q4 2018 | -8.7% | -19.4% | -15.6% | |
| Q3 2018 | -10.6% | -18.5% | -54.8% | |
| Q2 2018 | -2.9% | +15.2% | -21.0% | |
| Q1 2018 | +6.2% | +11.6% | +48.6% | |
| Q4 2017 | -4.7% | -1.1% | -13.4% | |
| Q3 2017 | -7.9% | -2.2% | +3.3% | |
| Q1 2017 | +0.5% | +4.9% | +3.4% | |
| Q4 2016 | -12.5% | -10.9% | -15.0% | |
| Q3 2016 | +1.3% | -4.5% | -6.8% | |
| Q2 2016 | +9.7% | +23.7% | -58.0% | |
| Q1 2016 | +12.9% | — | — | |
| Q4 2015 | -0.2% | — | — | |
| Q3 2015 | -6.2% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | +1.8% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | -2.5% | — | — | |
| Q2 2014 | +12.4% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | +11.2% | — | — | |
| Q3 2013 | +0.5% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | +4.7% | — | — | |
| Q1 2012 | -12.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2009 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro